RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Beijing Tongren Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07523737, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).

    Inclusion criterion 1

  3. ECOG performance status score 0-4.

    Inclusion criterion 4

  4. White blood cell count ≥ 3×10⁹/L; absolute neutrophil count ≥ 1.0×10⁹/L; platelet count ≥ 50×10⁹/L.

    Inclusion criterion 7

    Serum creatinine ≤ 1.5 mg/dL; creatinine clearance ≥ 50 mL/min.

    Inclusion criterion 8

    ALT and AST ≤ 3× upper limit of normal (ULN); total bilirubin ≤ 2× ULN.

    Inclusion criterion 9

  5. History of immunodeficiency, including positive HIV status, other acquired or congenital immunodeficiency disorders, or history of organ transplantation;

    Exclusion criterion 6

  6. Female patients who are pregnant or breastfeeding;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07523737, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).
  • Disease progression or relapse after prior treatment with high-dose methotrexate and/or BTK inhibitors.
  • Age between 18 and 75 years.
  • ECOG performance status score 0-4.
  • Expected overall survival > 3 months.
  • No known hypersensitivity to any study drug.
  • White blood cell count ≥ 3×10⁹/L; absolute neutrophil count ≥ 1.0×10⁹/L; platelet count ≥ 50×10⁹/L.
  • Serum creatinine ≤ 1.5 mg/dL; creatinine clearance ≥ 50 mL/min.
  • ALT and AST ≤ 3× upper limit of normal (ULN); total bilirubin ≤ 2× ULN.
  • Signed written informed consent.

Exclusion Criteria:

  • Presence of another malignant tumor requiring active pharmacological or surgical intervention at present;
  • Female patients who are pregnant or breastfeeding;
  • Patients (male or female) of reproductive potential who are unwilling to use or fail to use effective contraceptive measures;
  • Known hypersensitivity to any study drug or any excipient ingredients of these products;
  • Active infection (determined by the investigator);
  • History of immunodeficiency, including positive HIV status, other acquired or congenital immunodeficiency disorders, or history of organ transplantation;
  • Documented history of neurological or psychiatric disorders, including epilepsy or dementia;
  • Documented history of autoimmune diseases (except Hashimoto's thyroiditis or thyroid dysfunction);
  • Any severe comorbidity that, in the investigator's judgment, would compromise patient safety or interfere with the completion of the study.

Quoted from ClinicalTrials.gov, NCT07523737, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07523737, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07523737